Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma (ASMAVIE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01078688
First received: February 25, 2010
Last updated: January 28, 2013
Last verified: January 2013
  Purpose

Evaluation of the frequency of limitation of activity, depending on gender and age-group, in patients with persistent asthma consulting a general practitioner


Condition
Persistent Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of the Frequency of Limitation of Activity, Depending on Gender and Age-group, in Patients With Persistent Asthma Consulting a General Practitioner

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To describe the frequency of limitations of activities in patients with persistent asthma depending on gender and age-group. [ Time Frame: Last 3 months / once ] [ Designated as safety issue: No ]
  • To describe, depending on gender and age-group, the nature of the activities limited, the degree of limitation and the impact on the patient's daily life. [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To describe the nature of the activities limited, the degree of limitation and the impact on the patient's daily life according to the level of asthma control [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]
  • To describe, depending on gender and age-group, the activities that need to be specifically investigated in routine clinical practice due to their greater impact on the patient's quality of life, and which could indicate poorly controlled asthma [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]
  • To describe the main characteristics and initial management for all patients of the survey [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]

Enrollment: 1942
Study Start Date: March 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First 3 consecutive patients with persistent asthma seen by general practitioner receiving long-term maintenance treatment with inhaled steroids

Criteria

Inclusion Criteria:

  • persistent asthma receiving long-term maintenance treatment with inhaled steroids (alone or in combination with other drugs)

Exclusion Criteria:

  • Patients with a diagnosis of COPD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01078688

  Show 728 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Pascal Piedbois AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01078688     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2009/2
Study First Received: February 25, 2010
Last Updated: January 28, 2013
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Limitations of activities
persistent asthma
general practitioner
frequency of limitations of activities
depending on gender and age-group

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on August 28, 2014